-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319

Benzinga·08/19/2026 10:07:22
Listen to the news
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.